Novartis/Schering AG Re-Evaluating PTK/ZK Due To Low Probability Of Survival Benefit
This article was originally published in Pharmaceutical Approvals Monthly
Novartis and Schering AG plan to re-evaluate their development strategy for PTK/ZK 787 (vatalanib) following an interim analysis showing a low probability of a survival benefit in the second-line metastatic colorectal cancer setting
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class